A purified recombinant organophosphorus acid anhydrase protects mice against soman.
Since pharmacologic treatments of organophosphorus anticholinesterases (OPs) are nearing their practical limit other types of treatment are being sought. One approach is the prophylactic administration of scavengers that will detoxify OPs before they reach their critical target site. We have shown that mice which have been treated with a purified organophosphorus acid anhydride hydrolase (OPAH) are not measurably affected by doses of soman that are lethal to untreated animals. This result indicates that this approach is worthy of exploration and development for protecting military personnel and agriculture workers against OP intoxication.
Broomfield
C A
CA
Biochemical Pharmacology Branch, U.S. Army Medical Research Institute of Chemical Defense, Aberdeen Proving Ground, MD 21010-5425.
D000818:Animals; D043303:Aryldialkylphosphatase; D002265:Carboxylic Ester Hydrolases / Q000097:blood; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D007700:Kinetics; D007928:Lethal Dose 50; D051379:Mice; D009943:Organophosphorus Compounds / Q000494:pharmacology; D010744:Phosphoric Monoester Hydrolases / Q000494:pharmacology* / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000494:pharmacology; D012999:Soman / Q000037:antagonists & inhibitors / Q000633:toxicity*
D009943:Organophosphorus Compounds; D011994:Recombinant Proteins; C000516:2-(2-cresyl)-4H-1-3-2-benzodioxaphosphorin-2-oxide; D012999:Soman; D002265:Carboxylic Ester Hydrolases; D010744:Phosphoric Monoester Hydrolases; D043303:Aryldialkylphosphatase